載入...
Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds
Introduction. Given its efficacy and safety, NexoBrid™ (NXB) has become part of our therapeutic options in burns treatment with satisfactory results. However, no cost analysis comparing NXB to the standard of care (SOC) has been carried out as of today. Aim. To assess the cost of treatment with NXB...
Na minha lista:
| 發表在: | Biomed Res Int |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Hindawi Publishing Corporation
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5331316/ https://ncbi.nlm.nih.gov/pubmed/28293640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/9567498 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|